A detailed history of E Rn Financial, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, E Rn Financial, LLC holds 6,670 shares of EXAS stock, worth $387,593. This represents 0.07% of its overall portfolio holdings.

Number of Shares
6,670
Previous 6,670 -0.0%
Holding current value
$387,593
Previous $281,000 61.57%
% of portfolio
0.07%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

SELL
$41.33 - $74.26 $3,513 - $6,312
-85 Reduced 1.26%
6,670 $281,000
Q3 2023

Nov 06, 2023

BUY
$65.94 - $99.04 $1,780 - $2,674
27 Added 0.4%
6,755 $460,000
Q2 2023

Aug 10, 2023

SELL
$62.68 - $95.05 $31,402 - $47,620
-501 Reduced 6.93%
6,728 $631,000
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $4,552 - $7,972
150 Added 2.12%
7,229 $357,000
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $226,315 - $349,490
7,079 New
7,079 $230,000
Q2 2022

Aug 02, 2022

SELL
$35.61 - $76.23 $155,580 - $333,048
-4,369 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$57.56 - $82.54 $61,358 - $87,987
1,066 Added 32.27%
4,369 $305,000
Q4 2021

Feb 11, 2022

SELL
$72.5 - $100.68 $1,522 - $2,114
-21 Reduced 0.63%
3,303 $257,000
Q2 2021

Aug 06, 2021

BUY
$93.66 - $139.27 $54,978 - $81,751
587 Added 21.45%
3,324 $413,000
Q1 2021

Apr 12, 2021

BUY
$116.57 - $155.01 $319,052 - $424,262
2,737 New
2,737 $361,000
Q4 2020

Feb 24, 2021

SELL
$99.61 - $142.12 $228,007 - $325,312
-2,289 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$72.92 - $102.01 $18,375 - $25,706
-252 Reduced 9.92%
2,289 $233,000
Q2 2020

Aug 13, 2020

BUY
$55.75 - $92.75 $141,660 - $235,677
2,541 New
2,541 $221,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track E Rn Financial, LLC Portfolio

Follow E Rn Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Rn Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on E Rn Financial, LLC with notifications on news.